<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284817</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP068</org_study_id>
    <nct_id>NCT00284817</nct_id>
  </id_info>
  <brief_title>Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer</brief_title>
  <official_title>Phase I Study of MEDI522, a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer or Other Solid Tumors Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      - Assess the safety and tolerance of a weekly MEDI522 regimen in patients with&#xD;
      irinotecan-refractory advanced CRC or other solid tumors refractory to standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Assess the safety and tolerance of a weekly MEDI 522 regimen in patients with&#xD;
           irinotecan-refractory advanced CRC.&#xD;
&#xD;
        -  Determine a Phase II recommended dose based on acceptable dose-limiting toxicity. Other&#xD;
           considerations such as pharmacokinetic parameters may also be factored into the&#xD;
           determination of a Phase II dose.&#xD;
&#xD;
      The secondary objectives of the study are to:&#xD;
&#xD;
        -  Assess any antitumor activity of MEDI-522 in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The recommended Phase II dose will be based on acceptable dose-limiting toxicity</measure>
    <time_frame>Study Days 0, 7, 14, 21, 28, 35, 42, and 49.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters may also be factored into the determination of a Phase II dose and; Tumor response</measure>
    <time_frame>Study Days 0, 28, 56, 84, 112, 140, 168, 196, 224, 252, 280, 308, 336, 357; and tumor response on Study Days 56, 112, 168, 224, 280, 336, and 387.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-522</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-522</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-522</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-522</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-522</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-522</intervention_name>
    <description>Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-522</intervention_name>
    <description>Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-522</intervention_name>
    <description>Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-522</intervention_name>
    <description>Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-522</intervention_name>
    <description>The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically-confirmed advanced CRC that has progressed through&#xD;
             an irinotecan-containing regimen for metastatic disease, or has recurred during, or&#xD;
             within 6 months of completing, an irinotecan-containing adjuvant regimen, or other&#xD;
             histologically-confirmed solid tumors refractory to standard therapy.&#xD;
&#xD;
          -  Age at least 18 years at the time of the first dose of study drug.&#xD;
&#xD;
          -  Both males and females are eligible. Sexually active females, unless surgically&#xD;
             sterile (or at least one year post-menopausal), must have used an effective method of&#xD;
             avoiding pregnancy (including oral or implanted contraceptives, IUD, female condom,&#xD;
             diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual&#xD;
             partner or sterile sexual partner) for 30 days prior to the first dose of study drug,&#xD;
             and must agree to continue using such precautions for 30 days after the final dose of&#xD;
             study drug. Sexually active females of reproductive potential must have a negative&#xD;
             serum b human chorionic gonadotropin (bhCG) pregnancy test within 3 days of start of&#xD;
             therapy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. ECOG criteria&#xD;
             are described in Appendix A.&#xD;
&#xD;
          -  Patients who had prior treatment with chemotherapy or radiotherapy or had prior&#xD;
             surgery are eligible for study entry if at least 4 weeks have past since their&#xD;
             treatment/surgery.&#xD;
&#xD;
          -  All toxicities related to prior treatment must have resolved and all surgical wounds&#xD;
             must have healed.&#xD;
&#xD;
          -  Prior immunotherapy with approved agents is allowable.&#xD;
&#xD;
          -  ANC ³1500/mm3, platelets ³100,000/mm3, hemoglobin &gt;10.0 g/dL, serum creatinine £1.5&#xD;
             mg/dL or calculated creatinine clearance &gt;50 mL/min, serum bilirubin £2.0 mg/dL, and&#xD;
             AST/ALT £5 times the upper limit of normal (ULN).&#xD;
&#xD;
          -  PT/PTT less than ULN or international normalized ratio (INR) less than 1.12.&#xD;
&#xD;
          -  Thyroxine (T4) and thyroid-stimulating hormone (TSH) within normal limits.&#xD;
&#xD;
          -  Written informed consent obtained from the patient prior to receipt of any study&#xD;
             medication or beginning study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or nursing.&#xD;
&#xD;
          -  Known brain metastases or primary brain tumors, symptomatic pleural effusion or&#xD;
             ascites requiring paracentesis.&#xD;
&#xD;
          -  Respiratory insufficiency requiring oxygen treatment, or lymphangitic involvement of&#xD;
             lungs.&#xD;
&#xD;
          -  Any evidence of hematemesis, melena, hematochezia, or gross hematuria.&#xD;
&#xD;
          -  A history of significant adverse events related to a previously administered humanized&#xD;
             monoclonal antibody.&#xD;
&#xD;
          -  A known human immunodeficiency virus (HIV) or hepatitis virus infection.&#xD;
&#xD;
          -  A prior myocardial infarction or angina, or uncontrolled hypertension (systolic blood&#xD;
             pressure &gt;150 mm Hg).&#xD;
&#xD;
          -  A prior stroke or transient ischemic attack.&#xD;
&#xD;
          -  An active infection requiring systemic antiinfective therapy.&#xD;
&#xD;
          -  Received an investigational agent in the last 4 weeks of initiation of study&#xD;
             treatment.&#xD;
&#xD;
          -  A requirement for palliative chemotherapy, hormonal therapy, or immunotherapy during&#xD;
             the course of the study.&#xD;
&#xD;
          -  Clinical evidence of bowel obstruction.&#xD;
&#xD;
          -  A history of other malignancies within the past 5 years (with the exception of basal&#xD;
             cell carcinoma of the skin or completely excised in situ carcinoma of the cervix).&#xD;
&#xD;
          -  A general medical or psychological condition or behavior, including substance&#xD;
             dependence or abuse that, in the opinion of the investigator, might not permit the&#xD;
             patient to complete the study or sign the informed consent.&#xD;
&#xD;
          -  Prior treatment with MEDI-522 or MEDI-523.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krista Arbaugh, Dir., Clinical Ops</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <last_update_submitted>May 27, 2008</last_update_submitted>
  <last_update_submitted_qc>May 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Luz Hammershaimb, M.D., V.P., Clinical Dev.</name_title>
    <organization>MedImmune LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

